Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.05.002 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Manish R Patel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL. Electronic address: mpatel@flcancer.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hematologic Neoplasms, Leukemia, Myeloid, Acute, Primary Myelofibrosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are implicated in tumorigenesis; the pan-PIM kinase inhibitor, INCB053914, demonstrated antitumor activity in hematologic malignancy preclinical models. PATIENTS AND METHODS: This phase 1/2 study evaluated oral INCB053914 alone or combined with standard-of-care agents for advanced hematologic malignancies (NCT02587598). In Parts 1/2 (monotherapy), patients (≥18 years) had acute leukemia, high-risk myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasm, myelofibrosis (MF), multiple myeloma, or lymphoproliferative neoplasms. In Parts 3/4 (combination therapy), patients had relapsed/refractory or newly diagnosed (≥65 years, unfit for intensive chemotherapy) acute myeloid leukemia (AML) or MF with suboptimal ruxolitinib response. RESULTS: Parts 1/2 (n = 58): 6 patients experienced dose-limiting toxicities (DLTs), most commonly aspartate aminotransferase/alanine aminotransferase-elevated (AST/ALT; each n = 4). Fifty-seven patients (98.3%) had treatment-emergent adverse events (TEAEs), most commonly ALT-elevated and fatigue (36.2% each); 48 (82.8%) had grade ≥3 TEAEs, most commonly anemia (31.0%); 8 (13.8%) had grade ≥3 ALT/AST-elevated TEAEs. Parts 3/4 (n = 39): for INCB053914 + cytarabine (AML; n = 6), 2 patients experienced DLTs (grade 3 maculopapular rash, n = 1; grade 3 ALT-elevated and grade 4 hypophosphatemia, n = 1); for INCB053914 + azacitidine (AML; n = 16), 1 patient experienced a DLT (grade 3 maculopapular rash). Two complete responses were observed (1 with incomplete count recovery). For INCB053914 + ruxolitinib (MF; n = 17), no DLTs occurred; 3 patients achieved best reduction of >25% spleen volume at week 12 or 24. CONCLUSION: INCB053914 was generally well tolerated as monotherapy and in combinations; TEAEs were most commonly ALT/AST-elevated. Limited responses were observed with combinations. Future studies are needed to identify rational, effective combination strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL. Electronic address: mpatel@flcancer.com.
- Tennessee Oncology, PLLC, Chattanooga, TN.
- Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
- Stephenson Cancer Center, Oklahoma University, Oklahoma City, OK.
- Yale University and Yale Cancer Center, New Haven, CT.
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Förderung
- NCI NIH HHS
Zitieren
APA
Patel, M. R., Donnellan, W., Byrne, M., Asch, A. S., Zeidan, A. M., Baer, M. R., Fathi, A. T., Kuykendall, A. T., Zheng, F., Walker, C., Cheng, L., Marando, C., & Savona, M. R. (2023). Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.05.002
Vancouver
Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, et al. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.05.002
BibTeX
@article{Patel2023,
author = {Patel, Manish R and Donnellan, William and Byrne, Michael and Asch, Adam S and Zeidan, Amer M and Baer, Maria R and Fathi, Amir T and Kuykendall, Andrew T and Zheng, Fred and Walker, Chris and Cheng, Lulu and Marando, Cindy and Savona, Michael R},
title = {Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.05.002}
}
EUVIMED